Section one: Contracting authority
one.1) Name and addresses
Velindre NHS Trust, NHS Wales Shared Services Partnership — Procurement Services (on behalf of All Wales LHB's and Trusts)
Procurement Services, 4th Floor, Companies House, Crown Way
Cardiff
CF14 3UB
Telephone
+44 2920903883
Country
United Kingdom
Region code
UKL - Wales
Internet address(es)
Main address
https://etenderwales.bravosolution.co.uk/
Buyer's address
https://nwssp.nhs.wales/ourservices/procurement-services/
one.2) Information about joint procurement
The contract is awarded by a central purchasing body
one.3) Communication
Additional information can be obtained from the above-mentioned address
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Licensed Bulk Medicines
two.1.2) Main CPV code
- 33600000 - Pharmaceutical products
two.1.3) Type of contract
Supplies
two.1.4) Short description
We are interested in buying the following list of products, in licensed bulk containers of up to the sizes noted below, to be available within a 5 year timeframe. We consider the availability in licensed bulk presentation to be a significant market advantage and are willing to consider entering contracts for supply with suppliers who can meet this presentation requirement for these products.
Estimated value in the Wales market of this list is £42,317,736.61 p/a at current prices.
The list is not exhaustive, and we are willing to consider other generic and biosimilar products if licensed bulk presentation can be offered.
Drug,Strength,Proposed Vial Size
ARSENIC TRIOXIDE,1mg/mL,
AZACITIDINE,25mg/mL,500mL
BEVACIZUMAB,25mg/mL,100mL - 250mL
BORTEZOMIB,2.5mg/mL,50mL
CALCIUM FOLINATE,10mg/mL,1000mL
CARBOPLATIN,10mg/mL,1000mL
CETUXIMAB,5mg/mL,250m – 500mL
CISPLATIN,1mg/mL,500mL - 1000mL
CYCLOPHOSPHAMIDE,20mg/mL,500mL
CYTARABINE,100mg/mL or 20mg/mL,250mL
DARATUMUMAB,20mg/mL,100mL – 250mL
DOCETAXEL,20mg/mL,250mL - 500mL
DOXORUBICIN,2mg/mL,1000mL
EPIRUBICIN,2mg/mL,1000mL
ETOPOSIDE,20mg/mL,500mL
FLUCLOXACILLIN,,3000mL
FLUOROURACIL,50mg/mL or 25mg /mL,250-500mL
INFLIXIMAB,10mg/mL,500mL - 1000mL
IRINOTECAN,20mg/mL,1000mL
NIVOLUMAB,10mg/mL,250mL
OXALIPLATIN,5mg/mL,500mL-1000mL
PACLITAXEL,6mg/mL,1000mL
PEMBROLIZUMAB,25mg/mL,100mL – 250mL
PEMETREXED,25mg/mL,100mL – 250mL
PIPERACILLIN & TAZOBACTAM,,3000mL
RITUXIMAB,10mg/mL,500mL
TOCILIZUMAB,20mg/mL,250mL
TRASTUZUMAB EMTANSINE,20mg/mL,100mL - 250mL
VEDOLIZUMAB,60mg/mL,250mL
VITLIPID N INFANT,N/A,250mL
Please inform us via the contact information above if you are able to provide these products.
two.1.5) Estimated total value
Value excluding VAT: £42,317,736.61
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UKL - Wales
two.2.4) Description of the procurement
We are interested in buying the following list of products, in licensed bulk containers of up to the sizes noted below, to be available within a 5 year timeframe. We consider the availability in licensed bulk presentation to be a significant market advantage and are willing to consider entering contracts for supply with suppliers who can meet this presentation requirement for these products.
Estimated value in the Wales market of this list is £42,317,736.61 p/a at current prices.
The list is not exhaustive, and we are willing to consider other generic and biosimilar products if licensed bulk presentation can be offered.
Drug,Strength,Proposed Vial Size
ARSENIC TRIOXIDE,1mg/mL,
AZACITIDINE,25mg/mL,500mL
BEVACIZUMAB,25mg/mL,100mL - 250mL
BORTEZOMIB,2.5mg/mL,50mL
CALCIUM FOLINATE,10mg/mL,1000mL
CARBOPLATIN,10mg/mL,1000mL
CETUXIMAB,5mg/mL,250m – 500mL
CISPLATIN,1mg/mL,500mL - 1000mL
CYCLOPHOSPHAMIDE,20mg/mL,500mL
CYTARABINE,100mg/mL or 20mg/mL,250mL
DARATUMUMAB,20mg/mL,100mL – 250mL
DOCETAXEL,20mg/mL,250mL - 500mL
DOXORUBICIN,2mg/mL,1000mL
EPIRUBICIN,2mg/mL,1000mL
ETOPOSIDE,20mg/mL,500mL
FLUCLOXACILLIN,,3000mL
FLUOROURACIL,50mg/mL or 25mg /mL,250-500mL
INFLIXIMAB,10mg/mL,500mL - 1000mL
IRINOTECAN,20mg/mL,1000mL
NIVOLUMAB,10mg/mL,250mL
OXALIPLATIN,5mg/mL,500mL-1000mL
PACLITAXEL,6mg/mL,1000mL
PEMBROLIZUMAB,25mg/mL,100mL – 250mL
PEMETREXED,25mg/mL,100mL – 250mL
PIPERACILLIN & TAZOBACTAM,,3000mL
RITUXIMAB,10mg/mL,500mL
TOCILIZUMAB,20mg/mL,250mL
TRASTUZUMAB EMTANSINE,20mg/mL,100mL - 250mL
VEDOLIZUMAB,60mg/mL,250mL
VITLIPID N INFANT,N/A,250mL
Please inform us via the contact information above if you are able to provide these products.
two.3) Estimated date of publication of contract notice
1 January 2025
Section four. Procedure
four.1) Description
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes